American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Berger
    Berger
  7. Baselga
    Baselga
  8. Reis-Filho
    Reis-Filho
  9. Cordon-Cardo
    Cordon-Cardo
  10. Schultz
    Schultz

Groups

  1. Department of Medicine (2074)
  2. Solid Tumor Oncology Division (1737)
  3. GSK Faculty (1623)
  4. Sloan Kettering Institute Faculty (794)
  5. Sloan Kettering Institute Postdocs (766)
  6. Department of Pathology and Laboratory Medicine (714)
  7. Human Oncology and Pathogenesis Program (677)
  8. Surgery (639)
  9. Breast Medicine Service (605)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (570)
Search Within
Formats
  1. Meeting Abstract (1996)
  2. Journal Article (1965)
  3. Editorial (41)
  4. Review (22)
  5. Conference Paper (14)
  6. Correspondence (4)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2074)
  2. Solid Tumor Oncology Division (1737)
  3. GSK Faculty (1623)
  4. Sloan Kettering Institute Faculty (794)
  5. Sloan Kettering Institute Postdocs (766)
  6. Department of Pathology and Laboratory Medicine (714)

More Groups

People
  1. David Solit (174)
  2. Marc Ladanyi (157)
  3. Neal Rosen (141)
  4. Clifford Hudis (140)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (5)
  2. 2024 (55)
  3. 2023 (63)
  4. 2022 (261)
  5. 2021 (233)
  6. 2020 (271)

More Years

Publications
  1. Cancer Research (2685)
  2. Clinical Cancer Research (1362)

Results (4047)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of parsaclisib-ruxolitinib combination therapy in myelofibrosis patients (Pts) with low vs higher baseline platelet count (PC): A subgroup analysis of data from a phase 2 study
    Meeting Abstract

    Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Tools for collecting pathologist annotations and understanding interobserver variability
    Meeting Abstract

    Elfer, K. N.; Blenman, K.; Dudgeon, S. N.; Garcia, V.; Ehinger, A.; Li, X. X.; Ly, A.; Peeters, D.; Werness, B.; Hanna, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
    Meeting Abstract

    Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Associations of inflammatory biomarkers with survival among patients with stage III colon cancer (CALGB/SWOG 80702 [Alliance])
    Meeting Abstract

    Cheng, E.; Qian, S.; Shields, A. F.; Cespedes Feliciano, E. M.; Nixon, A. B.; Shergill, A. P.; Guthrie, K. A.; Couture, F.; Kuebler, P.; Kumar, P.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
    Meeting Abstract

    Lonial, S.; Richard, S.; Matous, J. V.; Yee, A. J.; Shah, U.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Ailawadhi, S.; Richardson, P. G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer
    Meeting Abstract

    Ravi, A.; Gainor, J.; Arniella, M.; Stewart, C.; Freeman, S.; Awad, M. M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J. W.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Exploring the impact of infertility and its treatments on risk of ovarian cancer
    Meeting Abstract

    Lee, A. W.; Phung, M. T.; Jensen, A.; Wu, A. H.; Cramer, D. W.; Modugno, F.; Harris, H.; Doherty, J. A.; Schildkraut, J.; Terry, K. L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas
    Meeting Abstract

    Gounder, M. M.; Schwartz, G. K.; Jones, R. L.; Chawla, S. P.; Chua-Alcala, V. S.; Stacchiotti, S.; Wagner, A. J.; Cote, G. M.; Maki, R. G.; Kosela-Paterczyk, H.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors
    Meeting Abstract

    Shapiro, G. I.; Basu, B.; El-Khoueiry, A.; Postel-Vinay, S.; Im, S. A.; Rha, S. Y.; Friedman, C. F.; Italiano, A.; Kim, Y. M.; Lim, M. C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100
    Meeting Abstract

    Dy, G. K.; Govindan, R.; Velcheti, V.; Falchook, G. S.; Italiano, A.; Wolf, J.; Sacher, A. G.; Takahashi, T.; Ramalingam, S. S.; Dooms, C.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: